CLIMB BIO INC (CLYM:NASDAQ)
$9.82 -1.09 (-9.9908%)
Analysed CLIMB BIO INC (CLYM:NASDAQ) News Sources
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
26-05-2026
yahoo.com
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
05-06-2026
yahoo.com
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
11-06-2026
yahoo.com
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
06-08-2026
yahoo.com
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale?
18-08-2026
yahoo.com
Climb Bio to Present at Upcoming Investor Conferences
02-09-2026
yahoo.com
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
03-09-2026
advfn.com
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
03-09-2026
marketbeat.com
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
03-09-2026
yahoo.com
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
02-10-2026
yahoo.com
What is the current price of CLIMB BIO INC (CLYM:NASDAQ)?
The current price of CLIMB BIO INC (CLYM:NASDAQ) is $9.82.
CLIMB BIO INC (CLYM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is $-1.09.
CLIMB BIO INC (CLYM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is -9.9908%.
What is the most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent sentiment for CLIMB BIO INC (CLYM:NASDAQ) is .
SEC-8K** Filing Available For CLIMB BIO INC (CLYM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.